Swipe to change view · pinch to zoom
FOXO4-DRI 14 mg lyophilized research peptide vial, PRIMEGEN LABS front label. Buy FOXO4-DRI 14 mg from PrimeGen Labs — 98.7% purity lyophilized FOXO4-DRI peptide for laboratory research, third party tested by HPLC and mass spectrometry, supplied in a sealed 10 mL borosilicate vial with a batch-matched certificate of analysis.
Senolytic peptide
D-retro-inverso peptide referenced in p53 interaction and senescent-cell research.
Low stock · few lots left
Select strength
Quantity
Price
$194.00Shipping costs are calculated at checkout. Full shipping information · Refund & damage policy
FOXO4-DRI 14 mg is a lyophilized research peptide supplied by PrimeGen Co. (vial branded PRIMEGEN LABS) for laboratory research use only. D-retro-inverso peptide referenced in p53 interaction and senescent-cell research. Each lot is RP-HPLC assayed at 98.7% purity with a lot-matched certificate of analysis available digitally. It is not a drug, supplement, or cosmetic and is not for human or veterinary use.
FOXO4-DRI is catalogued under Research Peptides and Longevity & Cellular Research. Each lot ships with third-party certificate of analysis documentation, is released against our quality control process, and is dispatched from southern Virginia — see shipping information and the FAQ before ordering.
For laboratory research use only. Not for human or veterinary consumption.
Long-term
-20 °C, sealed, desiccated
In transit
Ambient stable up to 21 days
After reconstitution
2–8 °C, use within 21 days
Light exposure
Protect from direct light
Lot XX · HPLC + MS report issued by an independent laboratory. The released PDF is available on request.
Research summary: D-retro-inverso peptide referenced in p53 interaction and senescent-cell research.
FOXO4-DRI is a retro-inverso peptide built from D-amino acids in reversed sequence order, engineered to mimic the FOXO4 interaction surface while resisting proteolysis. It is a standard tool compound in senolytic research.
Designed to interfere with the FOXO4-p53 protein-protein interaction that sequesters p53 in the nucleus of senescent cells. Disruption is reported to permit p53 mitochondrial translocation and selective apoptosis of senescent, but not proliferating, cells in culture.
Listed fields describe where this sequence appears in published in vitro and preclinical literature. They are not indications, applications, or claims of effect.
Supplied lyophilized; typically reconstituted in sterile water or PBS. As a D-amino-acid construct it is markedly protease-resistant, which simplifies long-incubation culture work.
As a sealed lyophilized powder the material is stable for extended periods at -20 °C when kept desiccated and protected from light. Once in solution, stability shortens considerably: aqueous stocks are normally held at 2-8 °C for short term work or aliquoted and frozen for longer storage. Repeated freeze-thaw cycling is the most common cause of measurable potency loss.
Single sequence per vial, sealed under inert gas in USP Type I borosilicate glass with a butyl rubber stopper and crimped aluminium overseal. Each vial carries a printed PrimeGen label with product name, strength, lot number, manufacture and retest dates, storage temperature and a QR code linking to the lot record. Vials ship in a rigid foam insert inside a protective mailer at ambient temperature.
For laboratory research purposes only. Not intended for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease. Purchasers are responsible for complying with all applicable laws and regulations.
This dossier collects everything a laboratory typically needs before requisitioning FOXO4-DRI at the 14 mg presentation: how the sequence is characterised in published literature, how the material is assayed and released, how it should be stored and reconstituted, and where it sits inside the wider specialty research catalogue. Every unit is supplied as a sealed lyophilized powder at 98.7% and is sold exclusively for laboratory research use. It is not a drug, dietary supplement or cosmetic, and it is not intended for human or veterinary use.
FOXO4-DRI is a retro-inverso peptide built from D-amino acids in reversed sequence order, engineered to mimic the FOXO4 interaction surface while resisting proteolysis. It is a standard tool compound in senolytic research.
D-retro-inverso peptide referenced in p53 interaction and senescent-cell research. Investigators most often encounter this sequence in senolytic screening and senescence-associated beta-galactosidase assays and in foxo4-p53 protein-protein interaction studies, which is why the 14 mg vial is the format we release most frequently — it gives enough material for a full dose-response series at typical assay concentrations without leaving a large reconstituted surplus to store. This compound is catalogued at 2 strengths (10 mg, 14 mg), so a study can be scaled without changing lot chemistry.
Designed to interfere with the FOXO4-p53 protein-protein interaction that sequesters p53 in the nucleus of senescent cells. Disruption is reported to permit p53 mitochondrial translocation and selective apoptosis of senescent, but not proliferating, cells in culture.
Descriptions above summarise observations reported in peer reviewed in vitro and animal literature. They describe what has been measured in model systems and are not claims of effect, indications, or guidance for use in humans or animals. Laboratories designing new work should return to the primary literature for concentration ranges, vehicle selection and control design, because reported effects in this class are strongly assay dependent.
Published work involving FOXO4-DRI clusters into a small number of recurring experimental settings:
Because these are in vitro and preclinical contexts, the practical requirement on the material itself is consistency: a known mass of a single sequence, a stated purity, and a lot record that can be cited in a methods section. That is what the 14 mg vial and its accompanying certificate of analysis are designed to provide.
Each FOXO4-DRI lot is assayed in house by reverse-phase HPLC and then re-tested by an independent analytical laboratory using HPLC alongside mass spectrometry for identity confirmation. The HPLC trace establishes the chromatographic purity figure printed on the label — 98.7% for the current release — while the mass spectrometry step confirms that the observed molecular ion matches the expected mass for the sequence rather than a truncated or deletion analogue.
Certificates are issued digitally rather than enclosed in the shipment, which keeps the document versioned and retrievable long after the vial is consumed. You can view or request the current report from the certificates library, and the underlying chromatograms and spectra can be requested through laboratory support. Our full release criteria are documented on the quality control and laboratory standards pages.
Storage. Sealed 14 mg vials are held desiccated and protected from light. Short holding periods at 2-8 °C are routine; for longer storage the lyophilized cake is kept at -20 °C. Allow the vial to equilibrate to room temperature before breaking the seal so that atmospheric moisture does not condense onto the powder.
Reconstitution. Supplied lyophilized; typically reconstituted in sterile water or PBS. As a D-amino-acid construct it is markedly protease-resistant, which simplifies long-incubation culture work.
Stability. As a sealed lyophilized powder the material is stable for extended periods at -20 °C when kept desiccated and protected from light. Once in solution, stability shortens considerably: aqueous stocks are normally held at 2-8 °C for short term work or aliquoted and frozen for longer storage. Repeated freeze-thaw cycling is the most common cause of measurable potency loss.
Handling. Work with the reconstituted solution under standard laboratory containment, record the reconstitution volume and date against the lot, and label aliquots with the resulting concentration. Volumes and concentrations are set by your own protocol; nothing on this page is a dosing instruction.
The most common source of irreproducibility with lyophilized peptides is not the sequence itself but the arithmetic around it. A 14 mg vial contains a nominal peptide mass; the actual peptide content of any lyophilized cake also reflects counter-ion and residual moisture content, so laboratories reporting exact molar concentrations should either use the net peptide content figure from the lot certificate or determine content independently by amino acid analysis or quantitative UV. Using the published average mass of ~5194 g/mol, a full 14 mg vial reconstituted in 1 mL of diluent gives a convenient round stock concentration for serial dilution.
Three practical points recur in method sections for this class of material:
Where a study spans several weeks, aliquoting the reconstituted stock immediately and freezing single-use volumes avoids the freeze-thaw cycling that accounts for most of the potency drift observed in longitudinal work.
FOXO4-DRI is released at 10 mg, 14 mg. Larger presentations lower the cost per milligram but commit a laboratory to using or storing more reconstituted material; smaller vials suit pilot work, method development and screening plates where a single stock is consumed quickly. The 14 mg vial listed on this page is priced at $194.00. Whatever presentation you select, the underlying material comes from the same synthesis and release programme, so switching strength does not change the analytical profile.
Orders ship from our facility in Chase City, Virginia, within the United States only, and every shipment carries the research use restriction on the outer documentation. Vials travel at ambient temperature in a rigid insert; lyophilized peptide is stable for the transit window, and the material should be moved to its long term storage temperature on arrival. Research materials are non returnable once dispatched.
Laboratories sourcing FOXO4-DRI frequently reference Oxytocin 5 mg, Adamax 10 mg, P-21 12 mg and PE-22-28 8 mg alongside it, either as comparators in the same assay or as adjacent sequences in the same pathway literature.
This compound is catalogued under Research Peptides, Longevity & Cellular Research, Specialty Research. The complete research compound catalogue lists every sequence and strength we hold.
Background reading in the research library: What are research peptides?, Understanding lyophilized powders, Are research peptides legal to buy online?.
Ordering details, transit times and our US shipping guarantee are set out on the shipping policy page, and general purchasing and compliance questions are answered in the frequently asked questions. Terms of sale, including our no returns policy on research materials, are published on the terms page.
Every FOXO4-DRI release passes through the same programme: synthesis against a defined sequence, in-house RP-HPLC purity assay, independent third party HPLC and mass spectrometry confirmation, visual inspection of the lyophilized cake, and a documented fill and seal step under inert gas in USP Type I borosilicate glass. Material that fails any stage is not released, and the certificate published for a lot is the certificate generated for that specific synthesis — never a representative or historical document carried over from an earlier batch.
Laboratories evaluating FOXO4-DRI for the first time frequently ask for the raw analytical files rather than the summary certificate. Chromatograms, mass spectra and, where applicable, net peptide content data can be requested for any lot; our support team answers analytical questions directly rather than through a ticket queue. Institutional purchasing, repeat supply for multi-month studies and quotations for multiple strengths are handled the same way.
The characterisations summarised above are drawn from peer reviewed in vitro and preclinical publications indexed in PubMed and from the corresponding entries in ChEMBL, PubChem and UniProt. Searching the compound name “FOXO4-DRI” in those databases returns the primary sources for the mechanism and application notes on this page. PrimeGen Co. does not publish clinical data and makes no therapeutic claim for this or any other catalogue item.
For laboratory research use only. Not for human or veterinary use. Not a drug, supplement, food or cosmetic. Read our research use policy before ordering.
Each unit contains 14 mg of lyophilized FOXO4-DRI in a sealed vial. The lot matched certificate of analysis is available digitally on the Certificates page and is not physically enclosed in the shipment.
Every lot is assayed in house by RP-HPLC and then re-tested by an independent laboratory using HPLC and mass spectrometry. This lot reports 98.7%.
Reconstitution parameters depend on your protocol. Use bacteriostatic or sterile diluent, add slowly against the vial wall, and swirl rather than shake to avoid shearing the peptide.
Yes. Chromatograms and MS spectra for any lot can be requested through the certificates page or by contacting the laboratory support team.
No. FOXO4-DRI is supplied strictly as a laboratory research chemical. It is not a drug, dietary supplement, or cosmetic, it is not approved for human or veterinary use, and it must not be administered to humans or animals.
Sealed 14 mg vials are held desiccated, protected from light, and away from repeated temperature swings; 2-8 °C suits short holding periods while -20 °C is used for longer storage of the lyophilized cake. Once reconstituted, the solution is normally kept at 2-8 °C for near-term work or aliquoted into single-use volumes and frozen, since repeated freeze-thaw cycling is the most common cause of measurable potency loss.
Each vial is filled to a nominal 14 mg of lyophilized peptide, with a published average molecular weight of ~5194 g/mol. Because lyophilized peptide also carries counter-ion and residual moisture, laboratories reporting exact molar concentrations should use the net peptide content on the lot certificate or determine content independently.
Every lot is assayed in house by reverse-phase HPLC for chromatographic purity, then re-tested by an independent laboratory using HPLC alongside mass spectrometry to confirm that the observed mass matches the expected sequence rather than a truncated or deletion analogue. The release specification is ≥ 98% by RP-HPLC; this lot reports 98.7%.
No. Orders ship within the United States only, dispatched directly from our facility in Chase City, Virginia. Vials travel at ambient temperature in a rigid protective insert, and the lyophilized powder is stable across the transit window; move the material to its long-term storage temperature on arrival.
No. Research materials are non-returnable once dispatched, because chain-of-custody and storage conditions cannot be verified after a vial leaves the facility. If a shipment arrives damaged or a lot does not match its certificate of analysis, contact laboratory support and we will resolve it directly.
Pairs well with
Complementary compounds researchers run alongside FOXO4-DRI — never competing alternatives.
Complete your order
Laboratory consumables matched to 1 vial in your cart.
Bacteriostatic Water
30 mL
1 × 30 mL — one vial of diluent per 3 peptide vials
Sterile Syringes
10-pack · 1 mL
10-pack covers a standard order
Alcohol Prep Pads
100-pack
Septum decontamination before every draw
Vial Storage Case
25 slots
Keeps lots organised and light-protected
Each hub sequences the guides, quality documentation and bench notes for a single topic, so you can move from this page into a structured reading path rather than a flat index.
Other compounds catalogued alongside FOXO4-DRI in Specialty Research. All items are supplied for laboratory research use only.
Longevity & Cellular Research
Specialty Research
Specialty Research
Specialty Research
Background reading from the PrimeGen research library covering FOXO4-DRI and the analytical practices behind its documentation.
Explore further
Continue from FOXO4-DRI into compounds studied alongside it, the kits that include it, the analytical documentation behind this lot, and the library articles covering its category.
FOXO4-DRI · 14 mg
Low stock · few lots left